Skip to content

阿德莱克斯

US · ARDX #3380 按市值排名
3.09 -0.18 -5.50%
实时 - 追踪5344个代码 - 心跳于425秒前 · 2026-10-16 20:02

估值 各估值倍数与自身5年区间的对比

市净率 5.65 低于历史水平 第26百分位
5年平均 7.01 · 在Biotechnology中排名第391/513
市盈率 -14.17 处于历史正常水平 第64百分位
5年平均 -20.87 · 前瞻 336.35
市销率 1.87 低于历史水平 第0百分位
5年平均 13.05 · 前瞻 1.59 · 在Biotechnology中排名第38/387

同业对比 Biotechnology

公司 市值 市盈率(TTM) 市净率 股息率
阿德莱克斯 (ARDX) 797.80M -13.43 5.36 0.00%
Vertex Pharmaceuticals (VRTX) 126.66B 29.11 6.26 0.00%
Moderna (MRNA) 87.04B -27.32 12.87 0.00%
Regeneron Pharmaceuticals (REGN) 81.41B 19.57 2.57 0.46%
argenx SE (ARGX) 51.51B 31.21 6.12 0.00%
BeiGene (ONC) 41.96B 65.32 8.11 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★★☆ 合理价值4.66 经济护城河None 不确定性High

当前股价低于晨星合理价值估算50.8%。

合理价值

Ardelyx Inc earns a 4-star quantitative star rating, reflecting our opinion that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 30% discount to our quantitative fair value estimate of $4.66 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The company's balance sheet increases our quantitative valuation. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. For example, the firm's EBITDA/interest coverage ratio of -0.8 sits in the bottom 20% compared with peers globally. Although the firm's ability to cover interest payments with EBITDA is limited, shares could sharply rebound if economic circumstances change or recent investments reduce fears of default. We believe this is a sign that shares could be cheap.

On a different note, the firm's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to EBITDA ratio of 26.7, for example, falls in the top 20% globally. This suggests that the value of its enterprise value, or the value of its shares and debt, is a high multiple of the generated EBITDA. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has been a laggard relative to the broader universe over the past year. This underperformance makes the stock appear cheap, which portends a buying opportunity in light of other contributors to our model.

经济护城河

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

作者:Quantitative Equity Report

报价时间 2026-10-16 20:02:13 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

阿德莱克斯 讨论区 0 条评论

发表评论